|
|
Volumn 24, Issue 2, 2002, Pages 111-114
|
|
Burkitt's lymphoma: Single-centre experience with modified BFM protocol
|
|
Author keywords
Burkitt's lymphoma; Modified BFM protocol
|
|
Indexed keywords
CYCLOPHOSPHAMIDE;
CYTOSINE;
DEXAMETHASONE;
DOXORUBICIN;
ETOPOSIDE;
IFOSFAMIDE;
METHOTREXATE;
PREDNISOLONE;
VINCRISTINE;
ABDOMINAL DISEASE;
ADULT;
AGE;
ARTICLE;
BURKITT LYMPHOMA;
CANCER CHEMOTHERAPY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG MEGADOSE;
DRUG TOLERANCE;
FOLLOW UP;
HUMAN;
PRIORITY JOURNAL;
RELAPSE;
REMISSION;
STEM CELL TRANSPLANTATION;
TIME;
TOXICITY;
6-MERCAPTOPURINE;
ADOLESCENT;
ADULT;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ASPARAGINASE;
BURKITT LYMPHOMA;
COMBINED MODALITY THERAPY;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DISEASE-FREE SURVIVAL;
FEMALE;
GRANULOCYTE COLONY-STIMULATING FACTOR;
HEMATOLOGIC DISEASES;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
INFECTION;
LYMPHOMA, AIDS-RELATED;
MALE;
METHOTREXATE;
PREDNISONE;
RECURRENCE;
REMISSION INDUCTION;
TREATMENT OUTCOME;
VINCRISTINE;
|
|
EID: 0036046069
PISSN: 01419854
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1365-2257.2002.00429.x Document Type: Article |
|
Times cited : (13)
|
|
References (7)
|
